ADVENTRX Pharmaceuticals Inc. is Today's Focus Stock on MicroStockProfit.com
July 21 2010 - 6:50AM
MicroStockProfit.com announces an investment report featuring
ADVENTRX Pharmaceuticals Inc. (AMEX:ANX). The report includes
financial, comparative and investment analyses, and recent company
news that you need to know to make an educated investment decision.
Our trade alerts and ideas are provided free to investors.
Simply use your email address to subscribe with
http://www.microstockprofit.com to get the inside track on our next
red-hot alert.
The full report is available at:
http://www.microstockprofit.com/lp/ANX
ANX is trading above its 13-day moving average. While this is
normally considered to be a bullish sign, the moving average is
downward sloping, which means that investors have been liquidating
shares during this time period and tempers the bullishness of the
signal.
ADVENTRX Pharmaceuticals Inc. (ANX) is a development-stage
biopharmaceutical company. The Company's business is focused on
in-licensing, developing and commercializing product candidates for
the treatment of cancer. Its lead product candidates, ANX-530 and
ANX-514, are emulsion formulations of marketed chemotherapy drugs.
ANX is focused primarily on evaluating strategic options, including
the sale or exclusive license of one or more of its product
candidate programs, a strategic business merger and other similar
transactions. In October 2008, ANX announced that it had
discontinued active work on all product candidates other than
ANX-530 and ANX-514. Its wholly owned subsidiaries include SD
Pharmaceuticals Inc. (SDP) and ANX (Europe) Ltd.
Message Board Search for ANX:
http://www.boardcentral.com/boards/ANX
In the report, the analyst notes:
"ANX's net loss applicable to common stock for the first quarter
of 2010 was $4.9 million, or $0.48 per share, compared to a net
loss applicable to common stock of $3.2 million, or $0.87 per
share, for the same period in 2009. Included in the net loss
applicable to common stock for the first quarter of 2010 was a
non-cash, deemed dividend expense of $2.5 million incurred in
connection with the Company's January 2010 equity financing.
"ANX recently announced the results of
stability tests performed on samples of ANX-530 (vinorelbine
injectable emulsion), or Exelbine(TM), manufactured at the
Company's intended commercial manufacturing site. The nine-month
stability data are on track to support the submission of a New Drug
Application (NDA) for Exelbine."
To read the entire report visit:
http://www.microstockprofit.com/lp/ANX
See what investors are saying about ANX at penny stock forum
MicroStockProfit.com Disclosure
MicroStockProfit.com is not a registered investment advisor and
nothing contained in any materials should be construed as a
recommendation to buy or sell any securities. MicroStockProfit.com
is a Web site wholly owned by BlueWave Advisors, LLC. Neither
MicroStockProfit.com nor its affiliates have a beneficial interest
in the mentioned company; nor have they received compensation of
any kind for any of the companies listed in this communication.
Please read our report and visit our Web site,
MicroStockProfit.com, for complete risks and disclosures.
CONTACT: MicroStockProfit.com
Brian Johnson
1-888-307-2850
info@microstockprofit.com
Adventrx (AMEX:ANX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Adventrx (AMEX:ANX)
Historical Stock Chart
From Jul 2023 to Jul 2024